Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

39.70p
   
  • Change Today:
      0.20p
  • 52 Week High: 71.80
  • 52 Week Low: 34.50
  • Currency: UK Pounds
  • Shares Issued: 540.40m
  • Volume: 866,514
  • Market Cap: £214.54m
  • RiskGrade: 119

Alliance Pharma completes £60m Nizoral acquisition

By Iain Gilbert

Date: Friday 22 Jun 2018

LONDON (ShareCast) - (Sharecast News) - AIM-quoted speciality pharmaceutical company Alliance Pharma completed its £60m acquisition of Nizoral, a medical, anti-dandruff shampoo brand, on Friday.
Alliance acquired Nizoral from Janssen Pharmaceutica, a member of the Johnson & Johnson group, in order to boost its "successful and rapidly growing" Asia-Pacific distribution business and expects to generate "material earnings enhancement" in just its first year of ownership.

The acquisition was funded by an underwritten equity placing of new ordinary shares to raise gross proceeds of £34m and by a drawdown of £27.9m from Alliance's £35m extension to its debt facilities.

As a result of the placing, Alliance now has a total of 514.2m ordinary shares in issue.

As of 0940 BST, Alliance shares had lost 0.41% to 97.20p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 39.70p
Change Today 0.20p
% Change 0.51 %
52 Week High 71.80
52 Week Low 34.50
Volume 866,514
Shares Issued 540.40m
Market Cap £214.54m
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
79.58% above the market average79.58% above the market average79.58% above the market average79.58% above the market average79.58% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
67.77% below the market average67.77% below the market average67.77% below the market average67.77% below the market average67.77% below the market average
1.75% below the sector average1.75% below the sector average1.75% below the sector average1.75% below the sector average1.75% below the sector average
Income
8.33% below the market average8.33% below the market average8.33% below the market average8.33% below the market average8.33% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
89.08% below the market average89.08% below the market average89.08% below the market average89.08% below the market average89.08% below the market average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Final Interim
Ex-Div 22-Jun-23 22-Dec-22
Paid 18-Jul-23 19-Jan-23
Amount 1.18p 0.59p

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 66,726 @ 39.70p
16:35 196 @ 39.70p
16:35 738 @ 39.70p
16:35 62 @ 39.70p
16:35 661 @ 39.70p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin
Chair Camillo Pane

Top of Page